- Report
- December 2025
- 391 Pages
Global
From €4274EUR$4,799USD£3,727GBP
- Report
- January 2026
- 183 Pages
Global
From €3157EUR$3,545USD£2,753GBP
€3508EUR$3,939USD£3,059GBP
- Report
- May 2026
- 104 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- January 2026
- 450 Pages
Global
From €4453EUR$5,000USD£3,883GBP
- Report
- January 2026
- 180 Pages
Global
From €4007EUR$4,500USD£3,495GBP
- Report
- May 2025
- 220 Pages
Global
From €4448EUR$4,995USD£3,879GBP
- Report
- October 2025
- 100 Pages
United States
From €5299EUR$5,950USD£4,621GBP
- Report
- March 2026
- 960 Pages
Global
From €2939EUR$3,300USD£2,563GBP
- Report
- April 2026
- 240 Pages
Global
From €2939EUR$3,300USD£2,563GBP
- Report
- August 2025
- 191 Pages
Global
From €3157EUR$3,545USD£2,753GBP
€3508EUR$3,939USD£3,059GBP
- Report
- August 2025
- 182 Pages
Global
From €3157EUR$3,545USD£2,753GBP
€3508EUR$3,939USD£3,059GBP
- Report
- August 2025
- 190 Pages
Global
From €3157EUR$3,545USD£2,753GBP
€3508EUR$3,939USD£3,059GBP
- Report
- May 2026
- 382 Pages
Global
From €5210EUR$5,850USD£4,543GBP
- Report
- June 2025
- 190 Pages
Global
From €4007EUR$4,500USD£3,495GBP
- Report
- June 2025
- 607 Pages
Global
From €4274EUR$4,799USD£3,727GBP
- Report
- September 2025
- 380 Pages
Global
From €4408EUR$4,950USD£3,844GBP
- Report
- September 2025
- 313 Pages
Global
From €4408EUR$4,950USD£3,844GBP
- Report
- January 2026
- 240 Pages
Global
From €2226EUR$2,500USD£1,941GBP
- Report
- November 2025
- 120 Pages
Global
From €2939EUR$3,300USD£2,563GBP
- Report
- November 2025
- 160 Pages
Global
From €2493EUR$2,800USD£2,174GBP

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more